AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Response Surface Modeling of Remimazolam and Sevoflurane

RecruitingNAAges 20 Years - 80 YearsAllPusan National University Yangsan Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This prospective randomized open-label study aims to investigate the pharmacodynamic interaction between remimazolam and sevoflurane during general anesthesia using response surface modeling. Although remimazolam has favorable hemodynamic stability compared with propofol, its hypnotic effect may be less predictable and poorly correlated with conventional sedation monitoring indices such as the bispectral index (BIS). In clinical practice, remimazolam and sevoflurane are often combined during induction and maintenance of anesthesia; however, the optimal interaction between these agents remains unclear. This study will evaluate whether the interaction between remimazolam and sevoflurane is synergistic, additive, or infra-additive using two representative response surface interaction models: the Minto model and the Greco model. BIS values and predicted effect-site concentrations will be an

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adults aged 20 to 80 years * Scheduled for elective surgery under general anesthesia at Pusan National University Yangsan Hospital * American Society of Anesthesiologists (ASA) physical status I or II * Able to provide written informed consent Exclusion Criteria: * Known allergy to remimazolam or sevoflurane * Renal, hepatic, neuromuscular, or neurological disease * Use of medications affecting the central nervous system * Chronic psychoactive drug use * Ischemic heart disease * Pregnant women
๐Ÿ’Š

What it tests

  • Remimazolam (Byfavo)
  • Sevoflurane (Volatile Anesthetic)
๐Ÿ“

Where

1 site
Pusan National University Yangsan Hospital
Yangsan, South Korea
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy